Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2020

View Archived Issues

Novartis presents updated results from phase III COMBI-I study

First-in-human data show safety and early hemostatic efficacy of BAY-2599023

D6PV, a novel dual apoC-II mimetic peptide that lowers plasma triglycerides in vivo

Sumitomo Dainippon Pharma describes new Nav1.1 channel activators

Boehringer Ingelheim patents GABA(A) receptor subunits alpha5beta3gamma2 negative modulators

Thrombosis leads to early termination of phase II BAY-1093884 trial

Lentiviral IFN-alpha improves survival in mouse bladder cancer models

2019-nCoV more similar to bat than human SARS

CD47 knockout improves antitumor vaccine

Myelin is deregulated in autism spectrum disorder

Immunomic Therapeutics describes EBNA1-encoding cancer vaccine

AMT-060 gene therapy provides long-term factor IX activity in hemophilia B patients

Adverum reports new interim data from phase I trial of gene therapy ADVM-022 in wet AMD

Aerpio presents further phase Ib data on ocular formulation of AKB-9778

KSQ identifies novel target for development of eTIL therapies for refractory solid tumors

Gantenerumab arm of DIAN-TU study did not meet primary endpoint

New aflibercept 8 mg formulation to enter phase III trials for DME and wet AMD

Regeneron reports 2-year data from PANORAMA study of Eylea in diabetic retinopathy

Lilly reports topline results on solanezumab from DIAN-TU study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...